Another day, another Big Pharma executive jumping ship to biotech. On Tuesday morning, it was Omar Khwaja, M.D., Ph.D., who became chief medical officer at gene therapy specialist Voyager Therapeutics.
Khwaja was a top research executive at Roche, leaving his dual positions as global head of neuroscience translational medicine and global head of rare diseases to become CMO at the neuroscience biotech.
Experiencing a seven-year itch, Khwaja has an impressive history at the Swiss major, helping push its first clinical programs in gene therapy while working on some tough CNS and rare diseases including spinal muscular atrophy and Huntington’s disease.
But now, as with so many executives before him, biotech beckoned, and he swaps his seven-year tenure at a major pharma to a smaller, riskier company.
“We are delighted to welcome Omar to the Voyager team,” said Andre Turenne, president and chief executive of Voyager. “Omar brings tremendous relevant expertise and will play an instrumental leadership role in advancing our innovative pipeline of gene therapy programs.”
Voyager, a 2014 Fierce 15 winner, has been a mixed bag in recent years. A year ago, its CEO Steven Paul, M.D., unexpectedly stepped down, with no replacement; the Eli Lilly vet was eventually replaced by ex-Sanofi/Genzyme veteran Turenne.
That came about three months after partner Sanofi walked away from the Parkinson’s gene therapy covered by a major $845 million alliance with the company. The decision gave Voyager the full global rights to VY-AADC, but left it without a partner as it geared up for a pivotal global phase 2/3 clinical trial.
At the time, Voyager said Sanofi’s decision was a result of the Big Pharma’s desire to own the U.S. rights to the gene therapy.
But on the flip side, just after Paul left, AbbVie teamed up with Voyager on a tau protein-targeting program, paying $69 million upfront for an option on the Alzheimer’s disease candidate.
The biotech, with a market cap of around $290 million, saw its shares down 2% last night.
By Ben Adams
Source: Fierce Biotech
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.